南宫NG·28(中国)相信品牌力量

Shanghai, China – On March 22, the Project of "Development and Industrialization of Key Technologies in Minimally Invasive Treatment of Aortic Diseases," jointly developed by Shanghai MicroPort (Medical) Group Co., Ltd ("MicroPort®"), its subsidiary MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort® Endovascular"), Beijing Anzhen Hospital of Capital Medical University, and Changhai Hospital of the Second Military Medical University, won the First Prize of Shanghai Science and Technology Progress Award.

The Project of "Development and Industrialization of Key technologies in Minimally Invasive Treatment of Aortic Diseases" is a comprehensive solution for aortic diseases provided by MicroPort® Endovascular after years of research in interventional treatment of aortic diseases, including CRONUS™ Surgical Stent Graft System ("CRONUS™"), Hercules™-T Low Profile Stent-Graft ("HT-LP") and Delivery System, and Aegis™ Bifurcated Stent-Graft System ("Aegis™") and Delivery System, etc. CRONUS™ is the only stent-graft used in the thoracic surgery for DeBakey I aortic dissection. The stent elephant trunk procedure is to implant CRONUS™ into the descending aorta by the way of intervention, then combine CRONUS™ with vascular prostheses together to replace the disease area which involves arch and ascending aorta. The application of CRONUS™ has made the complex thoracic aortic surgery more convenient and safer, as it successfully combines traditional open surgery and advanced interventional approaches to transform two complicated surgery to only one, significantly reduces the prevalence of morbidity and mortality. HT-LP and Delivery System is designed for the endovascular treatment of descending thoracic aortic disease. It is the first thoracic aortic aneurysm ("TAA") stent to have low profile delivery system with 18F outer diameter, which would benefit patients with narrow introducing femoral artery, mostly Asian female patients. Its soft inner sleeves are made of PET, which makes it easier for the stent to cross the aortic arch. The rear release mechanism of bare stent leads to more precise and stable positioning and deployment. The product offers 0-10mm taper availability, in accordance with the pathological features of aortic dissection. The height-mutative main body stent improves the flexibility of the whole stent. Aegis™ and Delivery System is designed for the endoluminal treatment of bifurcated abdominal aortic aneurysm ("AAA") and is the only stent-graft with a unique unibody design in China, especially suitable for AAA with some narrow blood vessels. There is no risk of migration of the stent graft after implantation as the stent graft is seated on the abdominal aortic bifurcation stably. The unibody design allows easy operation with no need to connect modular limbs, prevent the occurrence of type III endoleak. Meanwhile, it offers customer-made designs. These innovative stents graft have revolutionized the open surgery repair, and largely reduce the mortality rate of patients. It is estimated that more than 30,000 patients are saved by these products. Meanwhile, several products in this Project are the first-of-its kind among domestically developed products, successfully breaking the monopoly of imported products, which significantly lowered patients' economic burden.

MicroPort® Endovascular primarily focuses on R&D, manufacturing, sales and technical support of the interventional medical devices, including AAA/TAA stent graft systems, surgical stent graft system, aortic balloon dilation catheter and peripheral vascular stents/balloons. Its devices are widely used in China's top hospitals and have been exported to countries and regions in South America and Southeast Asia. The First Prize of Shanghai Science and Technology Progress Award for the Project of "Development and Industrialization of Key Technologies in Minimally Invasive Treatment of Aortic Diseases" demonstrated the government authorities' recognition in the innovation abilities of MicroPort® Endovascular. In the future, MicroPort® and MicroPort® Endovascular will continue to strive for innovation to promote the development of independent brands and focused on creating a sound environment for innovation and an efficient mechanism to cultivate innovative talents, to provide patients with rapidly increasing high-end medical products pioneering in China and throughout the whole world.